Creatine supplementation (3 g/day) and bone health in older women: a 2-year, randomized, placebo-controlled trial.
Creatine supplementation could be a non-expensive, safe and effective dietary intervention to counteract bone loss. The aim of this study was to investigate whether long-term creatine supplementation can improve bone health in older, postmenopausal women. A double-blind, placebo-controlled, parallel-group, randomized trial was conducted between November 2011 and December 2017 in Sao Paulo, Brazil. Two hundred postmenopausal women with osteopenia were randomly allocated to receive either creatine monohydrate (3 g/day) or placebo over 2 years. At baseline and after 12 and 24 months, we assessed areal bone mineral density (aBMD; primary outcome), lean and fat mass (through dual X-ray absorptiometry), volumetric BMD and bone microarchitecture parameters, biochemical bone markers, physical function and strength, and the number of falls and fractures. Possible adverse effects were self-reported. Lumbar spine (p<0.001), femoral neck (p<0.001) and total femur aBMD (p=0.032) decreased across time; however, no interaction effect was observed (all p>0.050). Bone markers, microarchitecture parameters, and the number of falls/fractures were not changed with creatine (all p>0.050). Lean mass and appendicular skeletal muscle mass increased throughout the intervention (p<0.001), with no additive effect of creatine (p=0.731 and p=0.397, respectively). Creatine did not affect health-related laboratory parameters. Creatine supplementation over 2 years did not improve bone health in older, postmenopausal women with osteopenia, nor did it affect lean mass or muscle function in this population. This refutes the long-lasting notion that this dietary supplement alone has osteogenic or anabolic properties in the long run.